PBI-4547 Reverses Diabetes and Metabolic Syndrome through Regulation of Lipid/Glucose Metabolism, -Oxidation and Fibrosis in Liver and Whit

June 22, 2018

These results suggest that PBI-4547 offers the potential as a novel therapy for diabetes, liver fibrosis and obesity.

 

PBI-4547 reduces:

  • Blood glucose, cholesterol and triglycerides levels
  • Pro-inflammatory and pro-fibrotic markers in liver
  • Adipocyte size and fibrosis in WAT

 

PBI 4547 reduces:

  • Serum adiponectin to regulate energy homeostasis

 

PBI-4547 modulates biomarkers associated to:

  • Glucose and lipid metabolism
  • Fibrosis
  • Mitochondrial metabolism 
  • Browning of adipose tissue
Previous Flipbook
PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-
PBI-4050 Improves Metabolic Regulation and Diabetic Nephropathy through Reduction of ER Stress, Pro-Inflammatory/Fibrotic Markers, Galectin-

These results suggest that PBI-4050 is a strong potential candidate for the treatment of metabolic diseases...

No More Flipbooks